유리체강 내 항혈관내피세포성장인자 주입술 전의 예방적 안압강하제의 효과

Prophylactic Effects of a Fixed Dorsolamide/Timolol Combination on IOP Elevation before Intravitreal Anti-VEGF Injection

Purpose: The purpose of the present study was to investigate the prophylactic effects of a fixed combination of dorsolamide/ timolol on intraocular pressure (IOP) elevation before intravitreal anti-VEGF injection. Methods: A prospective, randomized clinical trial was conducted on 91 eyes of 91 patients undergoing intravitreal anti- VEGF injection. The eyes were randomly divided into 2 groups, the eyes which had used the fixed prophylactic dorsolamide/ timolol combination (group 1, 58 eyes) and the eyes which had not used the combination (group 2, 15 eyes). The IOP was measured one hour and 5 minutes prior to the procedure, 5 minutes interval up to 30 minutes after the procedure and one hour, 1 day, 7 days, and one month after the procedure. The IOP changes were analyzed. Results: The mean 5 minutes and 30 minutes postoperative IOPs were 14.12 ± 4.18 mm Hg and 10.87 ± 1.58 mm Hg in group 1 and 28.21 ± 3.16 mm Hg and 17.48 ± 2.34 mm Hg in group 2, respectively. After IVBI, the mean 5 min postoperative IOP was 12.17 ± 1.13 mm Hg in group 1 and 27.12 ± 3.35 mm Hg in group 2. After IVRI, the mean 5 minutes postoperative IOP was 15.98 ± 4.14 mm Hg in group 1 and 25.19 ± 1.04 mm Hg in group 2. Conclusions: Prophylactic use of a fixed dorsolamide/timolol combination before intravitreal anti-VEGF injection is an easy and safe method of preventing IOP elevation immediately after intravitreal injection of bevacizumab or ranibizumab. J Korean Ophthalmol Soc 2011;52(6):702-708